(27 days)
The Interlock-35 Fibered IDC Occlusion System is indicated for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures. This device is not intended for neurovascular use.
The Interlock - 35 Fibered IDC Occlusion System includes a coil manufactured from platinum-tungsten alloy that is mechanically attached to a coil delivery wire. This assembly is contained within an introducer sheath. The platinum coil contains synthetic fibers for greater thrombogenicity. The Interlock - 35 Fibered IDC Occlusion System is designed to be delivered under fluoroscopy through a 5F (1.70 mm) OD (0.035 in [0.89 mm] or 0.038 in [0.97 mm] inner lumen) Imager™ II Selective Diagnostic Catheter without side flushing holes. The interlocking delivery wire design allows the coil to be advanced and retracted before final placement in the vessel, thus aiding in more controlled delivery including the ability to withdraw the coil prior to deployment.
Here's an analysis of the acceptance criteria and study information based on the provided text:
1. Table of acceptance criteria and the reported device performance
| Acceptance Criteria Category | Reported Device Performance |
|---|---|
| Interlocking Arm to Delivery Wire Tensile Strength | Met predetermined acceptance criteria |
| Delivery Wire Bend Resistance | Met predetermined acceptance criteria |
| Introducer Sheath Deliverability | Met predetermined acceptance criteria |
| Device Preparation | Met predetermined acceptance criteria |
| Corrosion Resistance | Met predetermined acceptance criteria |
| Device Removal From Carrier Tube | Met predetermined acceptance criteria |
| Sterilization | Met predetermined acceptance criteria |
| Biocompatibility | Met predetermined acceptance criteria |
2. Sample sized used for the test set and the data provenance
The document does not specify the exact sample sizes used for each bench test conducted. It generally states that "The following bench testing was conducted for design elements and performance characteristics deemed appropriate to demonstrate equivalence to the predicate device." It also doesn't mention data provenance in terms of country of origin or whether a test set was retrospective or prospective, as the study described is a series of bench tests rather than a clinical study with patient data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
This information is not applicable to the provided document. The study described involves bench testing of a medical device (Interlock™ -35 Fibered IDC™ Occlusion System) rather than evaluating an AI medical device that requires expert-established ground truth from images or patient data.
4. Adjudication method for the test set
This information is not applicable to the provided document, as the study is bench testing and not a clinical study involving human readers or adjudicators.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done (or at least not reported in this document). The device is a vascular embolization system, not an AI software/device.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
This information is not applicable. The device is a physical medical device for embolization, not an algorithm or AI system.
7. The type of ground truth used
The "ground truth" for the bench tests would have been the established engineering specifications and performance standards for each test (e.g., minimum tensile strength, maximum bend resistance, etc.). The document states the device "met the predetermined acceptance criteria," indicating these criteria served as the ground truth.
8. The sample size for the training set
This information is not applicable. The device is a physical medical device, not a machine learning model that requires a training set.
9. How the ground truth for the training set was established
This information is not applicable for the same reason as above.
{0}------------------------------------------------
510(k) Summary
Per 21 CFR §807.92
| Submitter's Name and Address | Boston Scientific CorporationOne Scimed PlaceMaple Grove, MN 55311USA |
|---|---|
| Contact Name and Information | Maureen SundeenPrincipal of Regulatory AffairsPhone: 763-494-2903Fax: 763-494-2222Email: sundeenm@bsci.com |
| Date Prepared | October 16, 2013 |
| Proprietary Name | Interlock™ -35 Fibered IDC™ Occlusion System |
| Common Name | Vascular Embolization Devices |
| Classification | Class II per 21 CFR 870.3300Product Code: KRDReview Panel: Cardiovascular |
| Predicate Device | Interlock™ -35 Fibered IDC™ Occlusion System(K113651, January 11, 2013) |
NOV 1 4 2013### Intended Use / Indications for Use
The Interlock-35 Fibered IDC Occlusion Svstem is indicated for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures. This device is not intended for neurovascular use.
Device Description
The Interlock - 35 Fibered IDC Occlusion System includes a coil manufactured from platinum-tungsten alloy that is mechanically attached to a coil delivery wire. This assembly is contained within an introducer sheath. The platinum coil contains synthetic fibers for greater thrombogenicity. The Interlock - 35 Fibered IDC Occlusion System is designed to be delivered under fluoroscopy through a 5F (1.70 mm) OD (0.035 in [0.89 mm] or 0.038 in [0.97 mm] inner lumen) Imager™ II Selective Diagnostic Catheter without side flushing holes. The interlocking delivery wire design allows the coil to be advanced and retracted before final placement in the vessel, thus aiding in more controlled delivery including the ability to withdraw the coil prior to deployment.
{1}------------------------------------------------
Comparison of Technological Characteristics
The Interlock-35 Fibered IDC Occlusion System is similar in fundamental design, function, device materials, packaging, sterilization, operating principle, intended use / indication for use and fundamental technology as the predicate device. The modifications from the predicate device include changes to the coil, delivery wire, introducer sheath and carrier hoop design and materials for added pushability, deliverability, and to facilitate coil hydration. In addition, the DFU will provide instructions for flushing the device using the hand-injection setup which is an additional method for hydrating the coil.
Performance Data
The following bench testing was conducted for design elements and performance characteristics deemed appropriate to demonstrate equivalence to the predicate device. The Interlock-35 Fibered IDC Occlusion System met the predetermined acceptance criteria ensuring substantial equivalence to the predicate device. No new safety or performance issues were raised during testing.
- Interlocking Arm to Delivery Wire Tensile Strength .
- Delivery Wire Bend Resistance .
- Introducer Sheath Deliverability .
- Device Preparation .
- Corrosion Resistance o
- Device Removal From Carrier Tube �
- Sterilization .
- Biocompatibility �
Conclusion
. '
Boston Scientific has demonstrated that the modification made for the Interlock-35 Fibered IDC Occlusion System are substantially equivalent in fundamental design, technology, function, device materials, packaging, sterilization, operating principle, and intended use / indication for use as the predicate device, Interlock-35 Fibered IDC Occlusion System (K113651).
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image is a logo for the Department of Health & Human Services - USA. The logo is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter of the circle. In the center of the circle is a stylized image of a person with their arms outstretched.
November 14, 2013
Boston Scientific Corp. Maureen Sundeen Principal of Regulatory Affairs One Scimed Place Maple Grove, MN 55311-1566 US
Re: K133208
Trade/Device Name: Interlock-35 Fibered IDC Occlusion System Regulation Number: 21 CFR 870.3300 Regulation Name: Vascular Embolization Devices Regulatory Class: Class II Product Code: KRD Dated: October 16, 2013 Received: October 18, 2013
Dear Ms. Sundeen:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
{3}------------------------------------------------
Page 2 - Maureen Sundeen
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Bram D. Zuckerman -S
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
Special 510(k) Premarket Notification Interlock™ -35 Fibered IDC™ Occlusion System
Indications for Use
510(k) Number (if known):
Device Name: Interlock™ -35 Fibered IDC™ Occlusion System
Indications for Use:
The Interlock-35 Fibered IDC Occlusion System is indicated for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures. This device is not intended for neurovascular use.
Prescription Use × AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Bram D. Zuckerman -S 2013.11.14 12:26:01 -05'00'
Page 1 of _ 1
'
§ 870.3300 Vascular embolization device.
(a)
Identification. A vascular embolization device is an intravascular implant intended to control hemorrhaging due to aneurysms, certain types of tumors (e.g., nephroma, hepatoma, uterine fibroids), and arteriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in neurovascular applications are also not included in this classification, see § 882.5950 of this chapter.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 870.1(e).